EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy

Bindu Singh, Chivonne Moodley, Dhiraj K Singh, Ruby A Escobedo, Riti Sharan, Garima Arora, Shashank R Ganatra, Vinay Shivanna, Olga Gonzalez, Shannan Hall-Ursone, Edward J Dick, Deepak Kaushal und 2 weitere

JCI Insight · 24.01.2023 · 8 (2)

DOI: 10.1172/jci.insight.163101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, online erschienen am 24.01.2023. Verfasst von Bindu Singh und 13 weiteren Autor:innen. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The expression of indoleamine 2,3-dioxygenase (IDO), a robust immunosuppressant, is significantly induced in macaque tuberculosis (TB) granulomas, where it is expressed on IFN-responsive macrophages and myeloid-derived suppressor cells. IDO expression is also highly induced in human TB granulomas, and products of its activity are detected in patients with TB. In vivo blockade of IDO activity resulted in the reorganization of the granuloma with substantially greater T cells being recruited to the core of the lesions. This correlated with better immune control of TB and reduced lung M. tuberculosis burdens. To study if the IDO blockade strategy can be translated to a bona fide host-directed therapy in the clinical setting of TB, we studied the effect of IDO inhibitor 1-methyl-d-tryptophan adjunctive to suboptimal anti-TB chemotherapy. While two-thirds of controls and one-third of chemotherapy-treated animals progressed to active TB, inhibition of IDO adjunctive to the same therapy protected macaques from TB, as measured by clinical, radiological, and microbiological attributes. Although chemotherapy improved proliferative T cell responses, adjunctive inhibition of IDO further enhanced the recruitment of effector T cells to the lung. These results strongly suggest the possibility that IDO inhibition can be attempted adjunctive to anti-TB chemotherapy in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosisTuberculosis, PulmonaryAnimalsHumansGranulomaIndoleamine-Pyrrole 2,3,-DioxygenaseMacrophages

Stichwörter der Autor:innen

Antigen presentationImmunologyInfectious disease

Substanzen

Indoleamine-Pyrrole 2,3,-Dioxygenase

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NIH

Zitieren

APA

Singh, B., Moodley, C., Singh, D. K., Escobedo, R. A., Sharan, R., Arora, G., Ganatra, S. R., Shivanna, V., Gonzalez, O., Hall-Ursone, S., Dick, E. J., Kaushal, D., Alvarez, X., & Mehra, S. (2023). Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy. JCI Insight, 8(2). https://doi.org/10.1172/jci.insight.163101

Vancouver

Singh B, Moodley C, Singh DK, Escobedo RA, Sharan R, Arora G, et al. Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy. JCI Insight. 2023;8(2). doi:10.1172/jci.insight.163101

BibTeX
@article{Singh2023,
  author = {Singh, Bindu and Moodley, Chivonne and Singh, Dhiraj K and Escobedo, Ruby A and Sharan, Riti and Arora, Garima and Ganatra, Shashank R and Shivanna, Vinay and Gonzalez, Olga and Hall-Ursone, Shannan and Dick, Edward J and Kaushal, Deepak and Alvarez, Xavier and Mehra, Smriti},
  title = {Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy},
  journal = {JCI Insight},
  year = {2023},
  volume = {8},
  number = {2},
  doi = {10.1172/jci.insight.163101}
}
Kostenlos starten →